Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Symptom severity
[50] RCT 4-armed trial	129 people	50% reduction in Hamilton Anxiety Scale (HAM-A) score 19/31 (61%) with abecarnil (3–9 mg/day) 8/26 (31%) with placebo	RR 1.99 95% CI 1.05 to 3.78	Small effect size	abecarnil
[50] RCT 4-armed trial	129 people	50% reduction in HAM-A score with abecarnil (7.5–15 mg/day and 15–30 mg/day) with placebo	Reported no significant difference between higher doses of abecarnil and placebo		Not significant
[31] RCT 3-armed trial	310 people	Proportion of people with moderate improvement on the Clinical Global Impressions Scale (CGI) scores at 6 weeks 62% with abecarnil (7.5–17.5 mg/day) 56% with placebo	Reported no significant difference between abecarnil and placebo P value not reported		Not significant